Product NDC: | 10019-631 |
Proprietary Name: | Ampicillin and Sulbactam |
Non Proprietary Name: | Ampicillin sodium and Sulbactam sodium |
Active Ingredient(s): | 250; 125 mg/mL; mg/mL & nbsp; Ampicillin sodium and Sulbactam sodium |
Administration Route(s): | INTRAMUSCULAR; INTRAVENOUS |
Dosage Form(s): | INJECTION, POWDER, FOR SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 10019-631 |
Labeler Name: | Baxter Healthcare Corporation |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA065406 |
Marketing Category: | ANDA |
Start Marketing Date: | 20100224 |
Package NDC: | 10019-631-01 |
Package Description: | 10 VIAL in 1 PACKAGE (10019-631-01) > 4 mL in 1 VIAL (10019-631-31) |
NDC Code | 10019-631-01 |
Proprietary Name | Ampicillin and Sulbactam |
Package Description | 10 VIAL in 1 PACKAGE (10019-631-01) > 4 mL in 1 VIAL (10019-631-31) |
Product NDC | 10019-631 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Ampicillin sodium and Sulbactam sodium |
Dosage Form Name | INJECTION, POWDER, FOR SOLUTION |
Route Name | INTRAMUSCULAR; INTRAVENOUS |
Start Marketing Date | 20100224 |
Marketing Category Name | ANDA |
Labeler Name | Baxter Healthcare Corporation |
Substance Name | AMPICILLIN SODIUM; SULBACTAM SODIUM |
Strength Number | 250; 125 |
Strength Unit | mg/mL; mg/mL |
Pharmaceutical Classes | Penicillin-class Antibacterial [EPC],Penicillins [Chemical/Ingredient],beta Lactamase Inhibitors [MoA],beta Lactamase Inhibitor [EPC] |